Overview

ReVision Implant is a Belgian neurotech startup developing the Occular cortical visual prosthesis, an implantable brain device designed to restore functional vision in people with severe blindness by interfacing directly with the visual cortex. The company was founded in 2020 by Prof. Peter Janssen and Dr. Frederik Ceyssens, building on years of cortical-prosthesis research at KU Leuven. Rather than attempting to repair damaged eyes, retinas, or optic nerves, the device bypasses the entire upstream visual pathway and feeds visual signals (captured by an external camera) directly into cortical electrode stimulation patterns.

The Occular device

The Occular system targets patients whose blindness sits anatomically downstream of the retina, where retinal prostheses cannot help. The external camera captures visual information, processes it, and transmits patterns of stimulation to the cortical electrode array, which evokes patterns of artificial sight in the patient’s perception. The architecture is a cortical visual prosthesis, sitting in the same anatomical category as the Intracortical Visual Prosthesis (ICVP) consortium device (Illinois Institute of Technology / Rush / Johns Hopkins / UChicago) and Neuralink’s planned Blindsight implant.

Regulatory and funding progression

ReVision received FDA Breakthrough Device Designation for the Occular prosthesis in March 2026 and closed an oversubscribed €4 million seed round in May 2026 from private investors. The company has not publicly named a lead investor. Proceeds will fund continued development through the first-in-human trial cleared for Q3 2026 (with an October 2026 surgical-window cohort during scheduled brain surgeries to gather acute intraoperative data) and the early-stage clinical trial in blind volunteers expected in summer 2027.

A material portion of the proceeds is earmarked for in-house manufacturing infrastructure: ReVision began standing up its own cleanroom facilities approximately three months ahead of the financing close, with the intent of bringing critical manufacturing steps in-house ahead of clinical trials. For a Class III implantable device, vertical-integrated production is a regulatory and commercial moat.

Strategic position

ReVision Implant is one of four vision-restoration platforms in active clinical or regulatory progression in 2026, alongside ICVP (third implant completed 7 May 2026), Neuralink Blindsight (first-in-human targeted for 2026), and Science Corporation’s PRIMA sub-retinal photovoltaic chip (CE Mark submitted June 2025, EU approval targeted mid-2026). ReVision’s €4 million round positions it at a much smaller capital base than Neuralink or Science Corporation but extends the European-public-research neurotechnology pattern that has been visibly producing serial BCI and visual-prosthesis companies through 2026.